China Cognition and Aging Study (COAST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03653156|
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : October 30, 2019
The Cognition and Aging Study (COAST) was designed to establish a prospective cohort to clarify the clinical and genetic characteristics, pathogenesis, diagnosis, treatment of MCI, AD, and VCI in China to establish a national database, to develop a strategy for prevention of dementia. The overarching goals of the COAST are as follow:
- To construct a prospective cohort, then to establish database that provide not only comprehensive epidemiological data on the AD and dementia of Chinese elders, but also biological samples and laboratory and image data.
- To determine the conversion rates from MCI to dementia or AD and risk factors for the progression from MCI to dementia or AD.
- To identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of AD.
- To uncover novel risk genes for complex AD and identify the genes related pathogenesis of the disease.
|Condition or disease|
|Mild Cognitive Impairment Alzheimer Disease, Late Onset Familial Alzheimer Disease (FAD) Vascular Cognitive Impairment APOE Gene Cohort (Cognitive Normal Subjects)|
This study involved participants including amnestic mild cognitive impairment (aMCI), sporadic Alzheimer's disease (SAD), familial Alzheimer's disease (FAD), Vascular cognitive impairment (VCI), and APOE gene cohort (cognitive normal subjects). Research contents are as follow:
- Neuropsychological characteristics of Chinese aMCI, SAD, VCI: analyze the cognitive function, daily living ability and mental behavior symptoms using MMSE, MoCA, etc. during the baseline and follow-up period.
- Neuroimaging of Chinese aMCI, SAD, and VCI: explore the neuroimaging characteristics and disease evolution characteristics through the apocalyptic atrophy, cortical thickness of structure MRI, and standardized uptake values of functional imaging FDG-PET.
- Prevention of Chinese aMCI, SAD, and VCI: find the risk factors and environmental factors which were possible related to development of these disease, and propose a preventional strategy for dementia in China.
- Pathogenesis of Chinese aMCI, SAD, and VCI: test the investigator's findings (risk factors, genetic factors, environmental factors) in this cohort on animal models.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||25000 participants|
|Target Follow-Up Duration:||20 Years|
|Official Title:||China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China|
|Actual Study Start Date :||January 10, 2008|
|Estimated Primary Completion Date :||January 1, 2028|
|Estimated Study Completion Date :||January 1, 2028|
Amnestic mild cognitive impairment (MCI)
Mild cognitive impairment subjects with memory loss as predominant symptom
Sporadic Alzheimer's disease (SAD)
Mild to moderate sporadic Alzheimer's disease subjects
Familial Alzheimer's disease (FAD)
Familial Alzheimer disease subjects with known or unknown mutations
Vascular cognitive impairment (VCI）
Cognitive impairment subjects caused by cerebral small vessel disease, including vascular cognitive impairment no dementia, vascular dementia, mixes dementia
APOE gene cohort
Cognitive normal subjects with ApoE ε4 positive or negative
- The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design [ Time Frame: an average of 2 years ]
- The conversion rate of normal to MCI to AD in Chinese [ Time Frame: an average of 2 years ]
- The biomarkers for normal (pre-MCI), MCI and AD diagnosis [ Time Frame: an average of 2 years ]Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.
- The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels [ Time Frame: an average of 2 years ]Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03653156
|Contact: Jianping Jia, Doctorfirstname.lastname@example.org|
|Study Chair:||Jianping Jia, Doctor||Xuanwu Hospital of Capital Medical University|